The safety of ritodrine hydrochloride: Adverse effects on fetuses and newborns

Area of Science:

• Perinatal care
• Neonatal medicine
• Pharmacovigilance

Background:

• Premature birth poses significant risks to infants, necessitating effective treatments for imminent preterm labor.
• Ritodrine hydrochloride (Rito) is a commonly used tocolytic agent in Japan for managing preterm birth.
• Concerns regarding the safety of short-acting beta-agonists, including Rito, have emerged in Europe, prompting further safety investigations.

Purpose of the Study:

• To investigate the safety profile of Ritodrine hydrochloride (Rito) in treating imminent preterm birth.
• To specifically evaluate the adverse effects of Rito on fetuses and newborn infants.

Main Methods:

• Utilized the Japanese Adverse Drug Event Report (JADER) database from the Pharmaceuticals and Medical Devices Agency of Japan.
• Extracted and analyzed adverse event data associated with oral and injected Rito.
• Calculated reported odds ratios to compare Rito's adverse effects against other drugs.

Main Results:

• Oral Rito showed significantly higher odds ratios for fetal tachycardia, fetal bradycardia, neonatal hypoglycemia, and neonatal heart failure compared to other medications.
• Injected Rito was associated with significantly higher odds ratios for fetal tachycardia and neonatal hypoglycemia.
• Adverse event reports were more frequent for oral Rito compared to injectable formulations.

Conclusions:

• Ritodrine hydrochloride (Rito) administration, particularly oral, is associated with increased risks of specific adverse effects in fetuses and neonates.
• The findings suggest a need for careful consideration of Rito's risk-benefit profile in the management of preterm birth.
• Further research into safer alternatives or optimized administration protocols for tocolytic therapy is warranted.